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Background:  Blunted heart rate response (HRR) to regadenoson has been shown to be predictive of poor outcome in patients undergoing 
SPECT myocardial perfusion Imaging (MPI). The predictive value of this marker has not been evaluated in high risk patients with end stage 
renal disease (ESRD).
methods:  ESRD patients enrolled in the ASSUAGE and ASSUAGE-CKD trials (aminophylline vs. placebo administered 2 min following 
regadenoson) were prospectively followed for all-cause mortality. HRR was defined as 100*(max HR - baseline HR) / (baseline HR). 
Patients were divided in 4 quartiles based on the HRR following regadenoson.
results:  A total of 303 patients with ESRD [mean age 54 ± 13 years, 64% men, 56% diabetes, 23% coronary artery disease (CAD)] 
were prospectively followed for 32 ± 10 months. Aminophylline did not impact HRR. There were 44 (14.5%) deaths. Blunted HRR was 
associated with a stepwise increase in mortality (log-rank P = 0.001), Fig 1A. After adjusting for age, sex, diabetes, CAD, summed stress 
score (SSS), and ejection fraction, an impaired HHR of <28% (2 bottom quartiles) was associated with 5 fold increase in mortality (HR= 
5.4, P = 0.03), and added incremental value (Χ2 increase = 8.8, p = 0.03), Fig 1B. Similar findings were obtained after stratifying for the use 
of aminophylline versus placebo (interaction P value = 1.0).
conclusion:  Impaired HRR to regadenoson is a strong and independent predictor of all-cause mortality in ESRD patients undergoing 
SPECT MPI, irrespective of the use of aminophylline. 
